Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric and headache disorders. Understanding the basis of the long-lasting effects, however, will be critical for the continued use and development of this drug class. Several mechanisms, including biological and psychological ones, have been suggested to explain the long-lasting effects of psychedelics. Actions on the neuroendocrine system are some such mechanisms that warrant further investigation in the study of persisting psychedelic effects. In this report, we review certain structural and functional neuroendocrinological pathologies associated with neuropsychiatric disorders and cluster headache. We then review the effects that psychedelic drugs have on those systems and provide preliminary support for potential long-term effects. The circadian biology of cluster headache is of particular relevance in this area. We also discuss methodologic considerations for future investigations of neuroendocrine system involvement in the therapeutic benefits of psychedelic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 5×
“One of the most intriguing features of psychedelics’ therapeutic profile is the apparent persistence of therapeutic effects after limited exposure, such measures as antidepressant effects, cigarette smoking reduction/cessation (Grob et al., 2011; Gasser et al., 2015; Griffiths et al., 2016; Johnson et al., 2017a), and…”
BackgroundInfluentialNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“There are ongoing studies investigating the effects of psychedelics in depression, drug and alcohol addiction, and headache disorders (Ross, 2012; Carhart-Harris et al., 2016).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 4×
“…apparent persistence of therapeutic effects after limited exposure, such measures as antidepressant effects, cigarette smoking reduction/cessation (Grob et al., 2011; Gasser et al., 2015; Griffiths et al., 2016; Johnson et al., 2017a), and termination of cluster headache attacks (Sewell et al.,…”
BackgroundInfluentialNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 2×
“…level-dependent (BOLD) methods, after intravenous administration of psilocybin (2 mg) in healthy humans, which may hold relevance for treatment in cluster headache, although all brain regions of interest were found to have decreased blood flow in this particular study (Carhart-Harris et al., 2012).”
BackgroundMethodPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“…Gasser et al., 2015; Griffiths et al., 2016), obsessive-compulsive symptoms (Moreno et al., 2006), and alcohol and tobacco addictions (Garcia-Romeu et al., 2014; Bogenschutz et al., 2015; Johnson et al., 2017a,b), as well as enhance attitude, mood, and behavior (Griffiths et al., 2008, 2011, 2016).”
BackgroundTsuno, N., Besset, A., & Ritchie, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1008 · Cited by 1,084
Evoked axonal oxytocin release in the central amygdala attenuates fear response
Knobloch, H. S., Charlet, A., Hoffmann, L. C., Eliava, M., Khrulev, S., Cetin, A. H., Osten, P., Schwarz, M. K., Seeburg, P. H., Stoop, R., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.030 · Cited by 1,049 · cited 1×
“Oxytocin is a neuropeptide that plays a central role in social functions, particularly the attachment process, but also sexual behavior, maternal behavior, affiliation, and social memory (Insel, 1992; Insel, 1997; Van de Kar et al., 2001; Knobloch et al., 2012).”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“Pharmacology Classic serotonergic psychedelics are those compounds that bind and activate the 5-HT2A receptor and cause significant alterations in sensorium and consciousness (Vollenweider et al., 1998; Nichols, 2004, 2016; Preller et al., 2017).”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“For example, egr-2 expression was increased in rat cortical tissue cultures after LSD (10 µM), but not lisuride (10 µM), treatment (González-Maeso et al., 2007), though in a human study, LSD (100 µg p.o.) failed to alter expression of egr-1, -2, or -3 in peripheral blood at 1.5 or 24 h after…”
BackgroundInfluentialNichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 2×
“The 5-HT2C receptor is involved in anxiety, dopaminergic neurotransmission, regulation of body weight, and addiction (Nichols and Nichols, 2008; Vengeliene et al., 2015; Canal and Murnane, 2017).”
BackgroundMethodSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 1×
“…to treat depression and anxiety in cancer patients (Grob et al., 2011; Gasser et al., 2015; Griffiths et al., 2016), obsessive-compulsive symptoms (Moreno et al., 2006), and alcohol and tobacco addictions (Garcia-Romeu et al., 2014; Bogenschutz et al., 2015; Johnson et al., 2017a,b), as well as…”
BackgroundGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 1×
“More recently, LSD has been shown to improve quality of life in patients with life-threatening disease (Gasser et al., 2014, 2015).”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 3×
“Additional systems associated with the action of psychedelics are dopaminergic, glutamatergic, and GABAergic systems (Vollenweider and Kometer, 2010; Nichols, 2016; Martin and Nichols, 2017).”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 2×
“of alcoholism (Krebs and Johansen, 2012) and it improved affect and sleep while reducing pain in cancer patients (Kast, 1967).”
BackgroundMethodA neurobiological basis of social attachment.
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.726 · Cited by 553 · cited 1×
“Serotonin2A receptor reduction is accompanied by significant attenuations in 5-HT-elicited PI hydrolysis signaling (Conn and Sanders-Bush, 1986; Ivins and Molinoff, 1991), as well as hallucinogen-elicited behaviors, such as head movements in rodents and rabbits (Leysen et al., 1989; Schindler et…”
BackgroundIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 2×
“) increased connectivity in frontal, parietal, and temporal cortices and bilateral thalami (Tagliazucchi et al., 2016).”
BackgroundInsel, T. R. (1992) · Psychoneuroendocrinology · doi:10.1016/0306-4530(92)90073-g · Cited by 487
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 2×
“The significance of such factors as intention, expectancy, preparation, and social setting in treatment outcomes is well recognized (Klosterhalfen and Enck, 2008; Hartogsohn, 2016).”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 3×
“As measured by single photon emission tomography (SPECT), oral ayahuasca (2.2 mL/kg solution containing 0.8 mg/mL DMT) increased cerebral blood flow in the left nucleus accumbens, right insula, and left subgenual area, regions associated with mood regulation (Sanches et al., 2016).”
BackgroundMethodInfluentialHasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 1×
“Vollenweider et al. (1997) reported that psilocybin (∼0.35 mg/kg p.o.) increased glucose metabolism in the brains of healthy human volunteers, increases in cortical regions being greater than those in subcortical regions (e.g., putamen).”
BackgroundInfluentialSouêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396 · cited 3×
“The disrupted circadian rhythm is further supported clinically, as symptoms of depression show diurnal variation (Souetre et al., 1989) and sleep disturbance is common in depressed individuals (Tsuno et al.”
BackgroundPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · cited 2×
“) was found to enhance suggestibility in human subjects as measured by the creative imagery scale (Carhart-Harris et al., 2015).”
BackgroundThe signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells
Provençal, N., Suderman, M. J., Guillemin, C., Massart, R., Ruggiero, A., Wang, D., Bennett, A. J., Pierre, P. J., Friedman, D. P., Côté, S. M., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1470-12.2012 · Cited by 312 · cited 2×
“While admittedly speculative, a powerful event holding significant salience could lead to epigenetic changes (Provencal et al., 2012; Black et al., 2013; Kaliman et al., 2014) or have effects on limbic circuitry that in turn alter neuroendocrine function, potentially reversing previously…”
BackgroundRapid changes in histone deacetylases and inflammatory gene expression in expert meditators
Kaliman, P., Álvarez-López, M. J., Cosín-Tomás, M., Rosenkranz, M. A., Lutz, A., & Davidson, R. J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.004 · Cited by 300 · cited 1×
“In addition to serotonergic receptors (Govitrapong et al., 1991; Kaminski et al., 1993), dopaminergic (Kim et al., 2010; Gonzalez et al., 2012) and sigma-1 (Jansen et al., 1990) receptors (or mRNA) have been identified in the pineal gland.”
BackgroundSrinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. P. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600571822 · Cited by 292
Oxytocin receptor polymorphisms and adult attachment style in patients with depression
Costa, B., Pini, S., Gabelloni, P., Abelli, M., Lari, L., Cardini, A., Muti, M., Gesi, C., Landi, S., Galderisi, S., et al. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.006 · Cited by 282
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“In mice, a single low dose injection of psilocybin (0.1 mg/kg i.p.) tended to stimulate hippocampal neurogenesis 2 weeks after injection, though a high dose (1.0 mg/kg i.p.) inhibited it (Catlow et al., 2013).”
BackgroundInfluentialHuman psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261 · cited 2×
“Unlike other psychedelics, however, DMT does not readily induce tolerance, which may be due to its short half-life or other yet unidentified factors (Strassman, 1996; Strassman et al., 1996).”
BackgroundInfluentialBlack, D. S., Cole, S. W., Irwin, M. R., Breen, E., St. Cyr, N. M., Nazarian, N., Khalsa, D. S., & Lavretsky, H. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.06.011 · Cited by 249 · cited 1×
“While admittedly speculative, a powerful event holding significant salience could lead to epigenetic changes (Provencal et al., 2012; Black et al., 2013; Kaliman et al., 2014) or have effects on limbic circuitry that in turn alter neuroendocrine function, potentially reversing previously…”
BackgroundGouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219 · cited 5×
“While other drugs, such as 3,4-methylenedioxymethamphetamine (MDMA; ecstasy), 1-9-tetrahydrocannabinol (1-9-THC), and ketamine, are often included in the category of psychedelic drugs and may have indirect effects on 5-HT2A receptors, their pharmacology is nevertheless distinct.”
BackgroundInfluentialHalberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response
Samuels, B. A., Anacker, C., Hu, A., Levinstein, M. R., Pickenhagen, A., Tsetsenis, T., Madroñal, N., Donaldson, Z. R., Drew, L. J., Dranovsky, A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4116 · Cited by 200
Intranasal oxytocin blocks alcohol withdrawal in human subjects
Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01958.x · Cited by 196
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 3×
“Genetics Single doses of LSD and DOI induce a number of immediate early genes in various regions of rodent brain, including cortex, amygdala, nucleus accumbens, and striatum (Nichols and Sanders-Bush, 2002; Martin and Nichols, 2017).”
BackgroundPsychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141 · cited 2×
“…(200 µg) (Schmid et al., 2015a; Strajhar et al., 2016), psilocybin (315 µg/kg) (Hasler et al., 2004), and ayahuasca (oral DMT portion 0.75 mg/kg) (Dos Santos et al., 2012) in humans approximately coincide with maximal serum hormone increases, a separation between these measures can also be shown.”
BackgroundInfluentialMacDonald, K., MacDonald, T. M., Brüne, M., Lamb, K., Wilson, M. P., Golshan, S., & Feifel, D. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.05.014 · Cited by 140
A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder
Olff, M., Langeland, W., Witteveen, A., & Denys, D. (2010) · CNS Spectrums · doi:10.1017/s109285290000047x · Cited by 135
Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M. (1989) · Psychopharmacology · doi:10.1007/bf00441948 · Cited by 132
Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00200-6 · Cited by 130
Childhood trauma and metabolic syndrome in men and women
Lee, C., Tsenkova, V., & Carr, D. (2014) · Social Science & Medicine · doi:10.1016/j.socscimed.2014.01.017 · Cited by 125 · cited 2×
“Childhood trauma (Lee et al., 2014) and repeated stressful life events in adulthood (Rutters et al., 2015) also increase the risk for metabolic syndrome.”
BackgroundKoch, S. B. J., van Zuiden, M., Nawijn, L., Frijling, J. L., Veltman, D. J., & Olff, M. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.018 · Cited by 123 · cited 6×
“Oxytocin is also likely involved in the pathophysiology of PTSD and there is reason to believe it could be helpful in its treatment, particularly given its role in stress responsiveness, fear conditioning, and social functioning, all of which are impacted by PTSD (Van de Kar et al., 2001; Olff et al., 2010).”
BackgroundInfluentialZhang, Y., Damjanoska, K. J., Carrasco, G. A., Dudas, B., D'Souza, D. N., Tetzlaff, J., Garcia, F., Hanley, N. R. S., Scripathirathan, K., Petersen, B. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09635.2002 · Cited by 107 · cited 2×
“, 2001) or intraparaventricular (blocked all except corticosterone) (Zhang et al., 2002) injection of 5-HT2A antagonist MDL100,907.”
BackgroundSelf-citationKarst, M., Halpern, J. H., Bernateck, M., & Passie, T. (2010) · Cephalalgia · doi:10.1177/0333102410363490 · Cited by 106
Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide
Kast, E. (1967) · The Psychiatric Quarterly · doi:10.1007/bf01575629 · Cited by 94 · cited 2×
“…that psychedelics may delay the onset and reduce total duration of REM sleep (Hobson, 1964; Depoortere and Loew, 1971; Brooks, 1975; Kay and Martin, 1978) might suggest that one of their therapeutic benefits in cluster headache stems from manipulation of the sleep period during which…”
BackgroundInfluentialJahn, A. L., Fox, A. S., Abercrombie, H. C., Shelton, S. E., Oakes, T. R., Davidson, R. J., & Kalin, N. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.039 · Cited by 61 · cited 2×
“The sigma-1 receptor has also been associated with psychotropic drug effects (Su et al., 1988; Jansen et al., 1990; Ruscher et al., 2011).”
BackgroundDiurnal variation in regional brain glucose metabolism in depression
Germain, A., Nofzinger, E. A., Meltzer, C. C., Wood, A., Kupfer, D. J., Moore, R. Y., & Buysse, D. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.043 · Cited by 60
Epigenetic alterations associated with war trauma and childhood maltreatment
Ramo‐Fernández, L., Schneider, A., Wilker, S., & Kolassa, I. (2015) · Behavioral Sciences & the Law · doi:10.1002/bsl.2200 · Cited by 59 · cited 2×
“Epigenetic modification of the glucocorticoid receptor gene, NR3C1, has been documented in such conditions as maternal stress, childhood maltreatment, and war trauma (Ramo-Fernández et al., 2015).”
BackgroundLee, M. R., Schwandt, M. L., Sankar, V., Suchankova, P., Sun, H., & Leggio, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.07.481 · Cited by 33 · cited 1×
“Post-mortem examination of patients with alcohol disorder showed reduced oxytocin mRNA levels as compared to controls (Lee et al., 2017).”
BackgroundShi, J., Landry, M., Carrasco, G. A., Battaglia, G., & Muma, N. A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.001 · Cited by 13 · cited 4×
“The hypothalamus contains those receptors activated by psychedelics, including 5-HT2A (Appel et al., 1990; Zhang et al., 2004; Shi et al., 2008), 5-HT2C (Marazziti et al., 1999), 5-HT1A (Albert et al., 1990; Zhang et al., 2004; Moser et al., 2010; Dos Santos et al., 2015), dopamine (Mukherjee et…”
BackgroundInfluential
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Psychedelics acutely modulate the Autonomic Nervous System (ANS) (39), neuroendocrine (232), and immune systems (233).”
BackgroundBarker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Giovannetti, C., Garcia Arce, S., Rush, B., & Mendive, F. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1789247 · Cited by 56
Metadata
- Authors
- Schindler, E. A. D., Wallace, R. M., Sloshower, J. A., & D’Souza, D. C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-01
- Volume
- 9
- Pages
- 177-177
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2792120884
- Cited by
- 47
- References
- 58
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.